qinlock Drug Patent Profile

When do Qinlock patents expire, and when can generic versions of Qinlock launch?

Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are seven patents protecting this drug.

This drug has forty patent family members in twelve countries.

The generic ingredient in QINLOCK is ripretinib. Additional details are available on the ripretinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Qinlock

Qinlock will be eligible for patent challenges on May 15, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2040. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for qinlock

International Patents:	40
US Patents:	7
Applicants:	1
NDAs:	1
Clinical Trials:	1
What excipients (inactive ingredients) are in qinlock?	qinlock excipients list
DailyMed Link:	qinlock at DailyMed

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for qinlock

NDA:

213973

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for qinlock

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Deciphera Pharmaceuticals LLC	Phase 1

See all qinlock clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for qinlock

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for qinlock

qinlock is protected by seven US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting qinlock

FDA Regulatory Exclusivity protecting qinlock

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes			Y	Y
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes

EU/EMA Drug Approvals for qinlock

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Deciphera Pharmaceuticals (Netherlands) B.V.	Qinlock	ripretinib	EMEA/H/C/005614 Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Authorised	no	no	yes	2021-11-18

International Patents for qinlock

When does loss-of-exclusivity occur for qinlock?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering qinlock around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2010503701
Australia	2007296450	Kinase inhibitors useful for the treatment of proliferative diseases
South Korea	20110074633	KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES